scholarly journals Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy

Theranostics ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 4672-4687
Author(s):  
Szu-Jung Chen ◽  
Li-Hsien Chen ◽  
Yu-Min Yeh ◽  
Chou-Ching K Lin ◽  
Peng-Chan Lin ◽  
...  
2019 ◽  
Vol 1866 (12) ◽  
pp. 118517 ◽  
Author(s):  
Hsiao-Han Lin ◽  
Szu-Jung Chen ◽  
Meng-Ru Shen ◽  
Yi-Ting Huang ◽  
Hsing-Pang Hsieh ◽  
...  

1999 ◽  
Vol 19 (3) ◽  
pp. 302-310
Author(s):  
Yukihiko Kohda ◽  
Katsuhiro Tsuchiya ◽  
Junkoh Yamashita ◽  
Masaki Yoshida ◽  
Takashi Ueno ◽  
...  

2004 ◽  
Vol 47 (20) ◽  
pp. 4799-4801 ◽  
Author(s):  
Robin L. Thurmond ◽  
Mary Pat Beavers ◽  
Hui Cai ◽  
Steven P. Meduna ◽  
Darin J. Gustin ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Floris J. van Dalen ◽  
Thomas Bakkum ◽  
Tyrza van Leeuwen ◽  
Mirjam Groenewold ◽  
Edgar Deu ◽  
...  

Cathepsin S is a lysosomal cysteine protease highly expressed in immune cells such as dendritic cells, B cells and macrophages. Its functions include extracellular matrix breakdown and cleavage of cell adhesion molecules to facilitate immune cell motility, as well as cleavage of the invariant chain during maturation of major histocompatibility complex II. The identification of these diverse specific functions has brought the challenge of delineating cathepsin S activity with great spatial precision, relative to related enzymes and substrates. Here, the development of a potent and highly selective two-step activity-based probe for cathepsin S and the application in multicolor bio-orthogonal correlative light-electron microscopy is presented. LHVS, which has been reported as a selective inhibitor of cathepsin S with nanomolar potency, formed the basis for our probe design. However, in competitive activity-based protein profiling experiments LHVS showed significant cross-reactivity toward Cat L. Introduction of an azide group in the P2 position expanded the selectivity window for cathepsin S, but rendered the probe undetectable, as demonstrated in bio-orthogonal competitive activity-based protein profiling. Incorporation of an additional azide handle for click chemistry on the solvent-exposed P1 position allowed for selective labeling of cathepsin S. This highlights the influence of click handle positioning on probe efficacy. This probe was utilized in multicolor bio-orthogonal confocal and correlative light-electron microscopy to investigate the localization of cathepsin S activity at an ultrastructural level in bone marrow-derived dendritic cells. The tools developed in this study will aid the characterization of the variety of functions of cathepsin S throughout biology.


Biochimie ◽  
2019 ◽  
Vol 166 ◽  
pp. 77-83 ◽  
Author(s):  
Ngoc Nguyen Lunde ◽  
Tatjana Bosnjak ◽  
Rigmor Solberg ◽  
Harald Thidemann Johansen

2019 ◽  
Author(s):  
Szu-Jung Chen ◽  
Meng-Ru Shen ◽  
Li-Hsien Chen ◽  
Hsiao-Han Lin ◽  
Shih-Han Hsu ◽  
...  

Cells ◽  
2020 ◽  
Vol 9 (9) ◽  
pp. 2021
Author(s):  
Natalie Fuchs ◽  
Mergim Meta ◽  
Detlef Schuppan ◽  
Lutz Nuhn ◽  
Tanja Schirmeister

Cathepsin S (CatS) is a secreted cysteine protease that cleaves certain extracellular matrix proteins, regulates antigen presentation in antigen-presenting cells (APC), and promotes M2-type macrophage and dendritic cell polarization. CatS is overexpressed in many solid cancers, and overall, it appears to promote an immune-suppressive and tumor-promoting microenvironment. While most data suggest that CatS inhibition or knockdown promotes anti-cancer immunity, cell-specific inhibition, especially in myeloid cells, appears to be important for therapeutic efficacy. This makes the design of CatS selective inhibitors and their targeting to tumor-associated M2-type macrophages (TAM) and DC an attractive therapeutic strategy compared to the use of non-selective immunosuppressive compounds or untargeted approaches. The selective inhibition of CatS can be achieved through optimized small molecule inhibitors that show good pharmacokinetic profiles and are orally bioavailable. The targeting of these inhibitors to TAM is now more feasible using nanocarriers that are functionalized for a directed delivery. This review discusses the role of CatS in the immunological tumor microenvironment and upcoming possibilities for a nanocarrier-mediated delivery of potent and selective CatS inhibitors to TAM and related APC to promote anti-tumor immunity.


2007 ◽  
Vol 21 (2) ◽  
pp. 204-209 ◽  
Author(s):  
T. Flannery ◽  
R. S. McConnell ◽  
S. McQuaid ◽  
G. Mcgregor ◽  
M. Mirakhur ◽  
...  

2000 ◽  
Vol 267 (3) ◽  
pp. 791-795 ◽  
Author(s):  
Katia Sol-Church ◽  
Jennifer Frenck ◽  
Robert W. Mason

Sign in / Sign up

Export Citation Format

Share Document